http://globenewswire.com/news-release/2014/09/29/669185/10100382/en/Catalyst-Pharmaceuticals-Announces-Positive-Top-Line-Phase-3-Data-From-Pivotal-Firdapse-Clinical-Trial-in-Patients-With-Lambert-Eaton-Myasthenic-Syndrome-LEMS.html

Comments

Popular posts from this blog

How-much-will-a-pack-of-joints-cost-the-future-of-mass-market-marijuana?

Cancer

Myasthenia Gravis vs. Lambert Eaton Syndrome ?